Moderna, Inc. (MRNA)’s “Got The Double Whammy,” Says Jim Cramer

We recently published 10 Stocks Jim Cramer Mentioned As He Talked About “Love Lost” Between Microsoft & OpenAI. Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer recently discussed.

Moderna, Inc. (NASDAQ:MRNA) has been one of the most ill-fated stocks in 2025. The shares have lost 38% year-to-date as the firm has struggled to diversify away from its mRNA vaccines amidst slipping demand for the products. For instance, Moderna, Inc. (NASDAQ:MRNA)’s full-year revenue guidance of $1.5 billion to $2.2 billion given during its second quarter earnings was lower than the earlier guidance of $1.5 billion to $2.2.5 billion. The reason behind the trimmed guidance was deferred revenue from its COVID vaccines. Cramer discussed Moderna, Inc. (NASDAQ:MRNA) in the context of RFK Jr:

“Hey that’s got the double whammy. It’s vaccine, got a guy at HHS doesn’t like it, they never did anything with the other one.”

The CNBC TV host discussed Moderna, Inc. (NASDAQ:MRNA) in May. Here is what he said:

“There’s gotta be some value in Moderna. There just has to be, but I’ve been against this stock for so long. I first discovered it at 18. Maybe that should be the price target.”

While we acknowledge the risk and potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRNA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.